Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers.
Standardisation of pathological evaluation of tissue responses to therapy permits robust stratification of patient outcomes for management decisions and allows comparison of results across clinical trials. In gynaecological pathology there are two major areas where pathological assessment of treatment response is currently used to determine ongoing therapy. High-grade serous carcinoma (HGSC) of tubo-ovarian origin frequently presents as high-stage disease and may be managed by neoadjuvant chemotherapy with debulking surgery. The chemotherapy response score (CRS) is a reproducible, validated three-tiered morphological scoring system to assess the response of HGSC to treatment. Interobserver agreement is shown to be substantial following online training, and women with CRS3 have significantly improved progression-free and overall survival. Low-grade endometrioid endometrial cancer and atypical hyperplasia/endometrioid intraepithelial neoplasia may be managed by progestogenic therapy in women who wish to preserve fertility or for whom medical co-morbidities preclude surgical management. The response to treatment is assessed histologically in successive endometrial biopsies. The histological parameters are well described, but the pathological classification of treatment response is still under development. Pathological assessment of the response to treatment is incorporated into clinical guidelines.
['Williams|Anthony T|AT|', 'Ganesan|Raji|R|https://orcid.org/0000-0002-6553-2855']
D000970:Antineoplastic Agents D016889:Endometrial Neoplasms D005260:Female D006801:Humans D020360:Neoadjuvant Therapy D010051:Ovarian Neoplasms D016896:Treatment Outcome
treatment response high-grade serous carcinoma chemotherapy response score progestogen conservative therapy endometrial carcinoma